Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers renoprotection. We determined whether canagliflozin decreases albuminuria and reduces renal function decline independently of its glycemic effects in a secondary analysis of a clinical trial in 1450 patients with type 2 diabetes receiving metformin and randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6–8 mg. End points were annual change in eGFR and albuminuria over 2 years of follow-up. Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups had eGFR declines of 3.3 ml/min per 1.73 m 2 per year (95% confidence interval [95% CI], 2.8 to 3.8), 0.5 ml/min per 1.73 m 2 per year (95% CI, 0.0 to 1.0), and 0.9 ml/min per 1.73 m 2 per year (95% CI, 0.4 to 1.4), respectively ( P <0.01 for each canagliflozin group versus glimepiride). In the subgroup of patients with baseline urinary albumin-to-creatinine ratio ≥30 mg/g, urinary albumin-to-creatinine ratio decreased more with canagliflozin 100 mg (31.7%; 95% CI, 8.6% to 48.9%; P =0.01) or canagliflozin 300 mg (49.3%; 95% CI, 31.9% to 62.2%; P <0.001) than with glimepiride. Patients receiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reductions in HbA1c of 0.81%, 0.82%, and 0.93%, respectively, at 1 year and 0.55%, 0.65%, and 0.74%, respectively, at 2 years. In conclusion, canagliflozin 100 or 300 mg/d, compared with glimepiride, slowed the progression of renal disease over 2 years in patients with type 2 diabetes, and canagliflozin may confer renoprotective effects independently of its glycemic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, SGLT2 inhibitors reduce kidney tubular glucose reabsorption, weight, systemic blood pressure, intraglomerular pressure, and albuminuria and slow GFR loss through mechanisms that appear independent of glycemia (31,(97)(98)(99)(100)(101).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [98]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Research works printed but not linked: 1
- 2015, Standards of medical care in diabetes–2015., Diabetes Care, 38, S1
Cited by
Items 201–300 of 360
Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New
Goldenberg, R., Berall, M. J., Chan, C. T., Cherney, D. Z. I., Lovshin, J. A., McFarlane, P. A., Senior, P. A., Verma, S., & Weinstein, J. J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.06.008 · Cited by 17
Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic Nephropathy?
Aziz, S., Ghadzi, S. M. S., Sulaiman, S. A. S., Hanafiah, N. H. M., & Harun, S. N. (2021) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_497_21 · Cited by 13
“[48] The Delay of IGT by a Healthy Lifestyle Trial (DELIGHT) randomized, double blind, placebo‑controlled trial demonstrated the effects of dapagliflozin alone or with combination of saxagliptin on glycemic control in patients with T2DM.”
Role of Estimated Glomerular Filtration Rate in Clinical Research: The Never-Ending Matter
Abenavoli, C., Provenzano, M., Ksiazek, S. H., Hu, L., Cuna, V., Manna, G. L., Comai, G., & Baraldi, O. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2501001 · Cited by 17
Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?
Çöpür, S., Yıldız, A. B., Basile, C., Tuttle, K. R., & Kanbay, M. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01422-w · Cited by 18
“SGLT2is also interfere in a reno-protective way with non-glycemic pathways [32, 48].”
BackgroundManski-Nankervis, J.-A. E., Thuraisingam, S., Sluggett, J. K., Kilov, G., Furler, J., O'Neal, D. N., & Jenkins, A. J. (2019) · BMC Family Practice · doi:10.1186/s12875-019-0915-x · Cited by 15
CHILTON, R. J., Dungan, K. M., Shubrook, J. H., & Umpierrez, G. E. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.09.008 · Cited by 13
Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease
Almaimani, M. K., Sridhar, V. S., & Cherney, D. Z. I. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000724 · Cited by 14
“in a secondary analysis of a clinical trial involving 1450 patients with T2D which demonstrated better annual eGFR decline and proteinuria profile with canagliflozin compared to glimepiride over two years despite only a modest difference in HbA1C between the two groups [11].”
ResultKoomen, J. V., Stevens, J., & Heerspink, H. J. L. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14318 · Cited by 13
Self-citationTye, S. C., de Vries, S. T., Wanner, C., Denig, P., & Heerspink, H. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786706 · Cited by 12
“Finally, in a head-to-head trial with glimepiride, the SGLT2 inhibitor canagliflozin slowed the decline in eGFR at equal glycemic control (Heerspink et al., 2017).”
BackgroundSelf-citationTang, E. H. M., Wong, C. K. H., Lau, K. T. K., Fei, Y., & Cheung, B. M. Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109071 · Cited by 13
Zhang, X., Zhong, Z., Li, Y., & Li, W. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3303 · Cited by 11
“of an RCT indicated that canagliflozin slowed the progression of renal disease over 2 years in patients with T2DM which was independent of its glycemic effects.(16) As for newer SGLT2 inhibitors, an observational study with 104-week follow-up showed that ipragliflozin significantly improved albuminuria in patients wit…”
BackgroundQiu, R., Balis, D. A., Capuano, G. A., Xie, J., & Meininger, G. E. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0201-z · Cited by 11
“In the 104-week study as add-on to metformin versus glimepiride [26], canagliflozin was associated with a slower rate in decline in eGFR compared with glimepiride, suggesting a potential renoprotective effect for canagliflozin [37].”
ResultSelf-citationCao, H., Liu, Y., Tian, Z., Lian, Y., Jia, J., Liu, M. R., & Dong, L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109033 · Cited by 12
SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist
Granata, A. R. M., Pesce, F., Iacoviello, M., Anzaldi, M., Amico, F., Catalano, M. R., Leonardi, G., Gatta, C., Costanza, G., Corrao, S., et al. (2022) · Frontiers in Nephrology · doi:10.3389/fneph.2022.867075 · Cited by 13
“reported that GFR decline was slowed down and that the proteinuria was reduced in T2DM patients treated with SGLT2i (40).”
BackgroundIrion, C. I., Williams, M. M., Capcha, J. M. C., Eisenberg, T., Lambert, G., Takeuchi, L. M., Seo, G., Yousefi, K., Kanashiro‐Takeuchi, R. M., Webster, K. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126674 · Cited by 12
Ma, C., Ju, B., Liu, J., Wen, L., Zhao, Y., Yang, J., & Hu, J. (2024) · Journal of Medicinal Food · doi:10.1089/jmf.2024.k.0175 · Cited by 10
“This suggests that metabolisms of methionine and tyrosine are expected to be potential intervention targets for treating DN.”
InfluentialWen, S., Yuan, Y., Li, Y., Xu, C., Chen, L., Ren, Y., Wang, C., He, Y., Li, X., Gong, M., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01985-2 · Cited by 14
Sugawara, M., Fukuda, M., Sakuma, I., Wakasa, Y., Funayama, H., Kondo, A., Itabashi, N., Maruyama, Y., Kamiyama, T., Utsunomiya, Y., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01438-w · Cited by 10
“Since SGLT2is exert a renal protective effect [31, 32] and improve proximal renal tubule function, luseogliflozin increased the production of erythropoietin in the kidney and hematopoiesis.”
BackgroundHadjadj, S., Cooper, M. E., Steubl, D., Petrini, M., Hantel, S., Mattheus, M., Wanner, C., & Thomas, M. C. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100783 · Cited by 10
“42-44 Indeed, SGLT2 inhibition is associated with an initial decrease in eGFR of 3-5 mL/min/1.73 m 2 shortly after treatment initiation, 6,16,45,46 which may lead to an un-derestimation of the true effect of SGLT2 inhibition to stabilize kidney function over a longer period of time.”
BackgroundInfluentialRecent Advances in Management of Diabetic Nephropathy
Din, U. A. S. E., Salem, M. M., & Abdulazim, D. O. (2017) · World Journal of Nephrology · doi:10.21767/2472-5056.100035 · Cited by 9
Hirai, T., Kitada, M., Monno, I., Oda, E., Hayashi, Y., Shimada, K., Takagaki, Y., Ogura, Y., Fujii, M., Konishi, K., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13502 · Cited by 9
“Furthermore, Heerspink et al.17 showed that canagliflozin slowed the progression of renal function decline independently of glycemic controls.”
Is GFR decline induced by SGLT2 inhibitor of clinical importance?
Günes-Altan, M., Bosch, A., Striepe, K., Bramlage, P., Schiffer, M., Schmieder, R. E., & Kannenkeril, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02223-0 · Cited by 12
Wang, M., & Zuo, L. (2025) · Cardiorenal Medicine · doi:10.1159/000545622 · Cited by 11
“Notably, these bene fi ts were attained when co-administered with background RAAS inhibitor therapy [26, 28].”
Plasma activity of the antioxidant enzymes in predicting diabetic nephropathy progression
Kovačević, M., Mališ, S., Pavlović, D., Kovačević, M., Savic-Radojevic, A. R., & Djukanović, L. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-03031-1 · Cited by 9
Mavrakanas, T. A., & Lipman, M. L. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.006 · Cited by 9
Parker, E. D., Wittbrodt, E. T., McPheeters, J., & Frías, J. P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13502 · Cited by 8
Lioudaki, E., Joslin, J. R., Trachanatzi, E., & Androulakis, E. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303082 · Cited by 11
Renal outcomes with sodium-glucose cotransporters 2 inhibitors
Sun, X., & Wang, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1063341 · Cited by 9
“In a larger and longer-term (2-year) clinical trial, 1,450 T2D patients receiving metformin were assigned to canagliflozin 100 mg or 300 mg and glimepiride 6-8 mg (77).”
BackgroundNunoi, K., Sato, Y., Kaku, K., Yoshida, A., & Suganami, H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13731 · Cited by 8
“This recovery of eGFRMDRD from the initial decrease was consistent with that shown in previous studies.(18,27) However, in this study, a significant increase in eGFRMDRD from baseline to Week 52 was observed.”
ResultAn evaluation of canagliflozin for the treatment of type 2 diabetes: an update
Minami, T., Kameda, A., & Terauchi, Y. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939675 · Cited by 10
SGLT-2 inhibitors: new horizons for rheumatologists
Chakrabarti, K., & McCune, W. J. (2024) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001030 · Cited by 10
An, H.-J., Jang, J. H., Lee, S., Kim, S. G., Song, H. J., Noh, H., & Kim, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111796 · Cited by 8
Jhaveri, U., & Vardesh, D. L. (2019) · Cureus · doi:10.7759/cureus.5455 · Cited by 8
“The recent increase in use of SGLT2i may be in light of their many added benefits including weight loss, reduced systolic blood pressure, reduced hospitalisations from decompensated heart failure, reduced cardiovascular mortality and reno-protection [2, 3, 8, 9].”
Pioli, M. R., Ritter, A. M. V., & Modolo, R. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx204 · Cited by 8
SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Gill, A., Gray, S. P., Jandeleit-Dahm, K. A. M., & Watson, A. M. D. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180417121246 · Cited by 9
A Review of the Renoprotective Effects of Novel Antidiabetic Agents
Leite, K., Long, A. M., Ostroff, M. L., Borges, L., & Braden, G. L. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020902344 · Cited by 9
“77).(10) Heerspink and colleagues conducted a post hoc analysis on the CANTATA-SU trial.”
MethodWilkinson, S., Tomlinson, L. A., Iwagami, M., Stirnadel-Farrant, H. A., Smeeth, L. L., & Douglas, I. (2018) · Wellcome Open Research · doi:10.12688/wellcomeopenres.14660.1 · Cited by 7
Wang, Y., Wang, Y., He, X., & Li, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554637 · Cited by 19
Women's health and kidney protective medications
Shankar, M., Ali, S., & Shah, S. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001000 · Cited by 6
SGLT2 inhibition: a new era in renoprotective medicine?
Muskiet, M. H. A., Heerspink, H. J. L., & van Raalte, D. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30222-x · Cited by 6
Self-citationAhmed, E. I., Shabaan, A. M., & Latif, A. K. M. A. (2019) · Current Drug Therapy · doi:10.2174/1574885514666191007094424 · Cited by 7
Inherited metabolic disorders associated with hypoglycaemia in adulthood: a narrative review
Dawson, C. (2021) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm-20-100 · Cited by 6
“Elimination of 1,5AG is enhanced by administration of sodium-glucose transporter inhibitors (SGLTi), otherwise known as the ‘gliflozins’ (18) and this class of drug is already proving to be effective in slowing the progression of diabetic nephropathy in diabetics independent of its glycaemic effect (19).”
BackgroundBerezin, A. Е., & Berezina, T. A. (2024) · Journal of International Medical Research · doi:10.1177/03000605241227659 · Cited by 7
“19,28 Moreover, SGLT2 inhibitors seem to show improving kidney function independently of their glycemic effects, 49 while they are able to reduce tubular cell glucotoxicity via inhibition of sodium transporters, modulating mitochondrial dysfunction and suppressing local and systemic inflammatory…”
BackgroundGupta, V., Willis, M. S., Johansen, P., Nilsson, A., Shah, M., Mane, A., & Neslusan, C. A. (2018) · Value in Health Regional Issues · doi:10.1016/j.vhri.2018.06.002 · Cited by 7
Lioudaki, E., Whyte, M., Androulakis, E. S., Stylianou, K., Daphnis, E., & Ganotakis, E. S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.731 · Cited by 6
“All groups showed small improvements in glycemic control, which, although were more pronounced with canagliflozin, could not account for the renal effects or changes in BP and body weight.(38) Consistently in another study, canagliflozin at both doses (100 and 300mg) significantly reduced median ACR compared to placeb…”
BackgroundResultSGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos, P. I., Divani, M., Eleftheriadis, T., Mertens, P. R., & Liakopoulos, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180524114033 · Cited by 8
Interventions for the prevention and management of cardiometabolic multiple long-term conditions
Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P., Lawson, C. A., Seidu, S., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 6
Yu, T., Xiao, J., Li, M., Cheng, S., Cai, R., Huang, L., Yu, H., Li, J. Y., Zhang, Y.-Y., & Wang, Y. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2471529 · Cited by 5
“Canagliflozin has similarly shown protective effects on the heart and kidneys in the CANVAS trial [6,7].”
Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
Zhou, T., Yao, K., Xie, Y., Lin, Y., Wang, J., & Chen, X. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230804103643 · Cited by 8
Zhang, C., Zhu, B., Feng, Y., Cheng, Z., Cai, X., Feng, L., Li, J., & Lü, X. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02220-x · Cited by 6
“Thus, an early eGFR decline may not necessarily be detrimental and might be a prerequisite for a protective effect [17, 27].”
Insulin and Other Hypoglycemic Drugs
Pittman, J. M., Schalliol, L. A., & Ray, S. D. (2017) · Side effects of drugs annual · doi:10.1016/bs.seda.2017.06.026 · Cited by 7
Dalan, R. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000201 · Cited by 6
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
Tomlinson, B., & Li, Y. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2276180 · Cited by 6
“In patients with T2D, eGFR decreases more rapidly with age than in people without T2D and canagliflozin can contribute to slow progression of renal function decline in T2D patients with ACR ≥30 mg/g [54].”
BackgroundTanton, D., Duh, M. S., Lafeuille, M., Lefèbvre, P., Pilon, D., Zhdanava, M., Émond, B., Inman, D., & Bailey, R. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1444591 · Cited by 5
Weir, M. R. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1624582 · Cited by 7
“important role in decreasing intraglomerular pressure [35].”
Empagliflozin’s role in early tubular protection for type 2 diabetes patients
Zhang, C., Ren, W., Lü, X., Feng, L., Li, J., & Zhu, B. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00881-0 · Cited by 4
“Particularly, the mild decrease in eGFR may be related to the initial use of SGLT2 inhibitors, and this decline is reversible and may be associated with long-term renal protection (Heerspink et al. 2017; Elmore et al. 2014; Kohan et al. 2014; Yoshida 2020; Kjaergaard et al. 2022).”
BackgroundTallowin, S., Abel, B., Mysore, B. S., Mares, J. A., Anderson, J. A., Propper, B. W., Stewart, I. J., & Burmeister, D. M. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006501 · Cited by 4
Kidney health for all: caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, Á., Yadla, M., et al. (2026) · Kidney International · doi:10.1016/j.kint.2025.12.020 · Cited by 8
Park, G., Choi, B., Kang, S., Kim, B., & Chang, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185259 · Cited by 5
“The acute phase is typically observed when patients first initiate SGLT2 inhibitors, and eGFR subsequently stabilized [24].”
BackgroundBibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
Sun, H. Y., Wang, Z., Wang, Y., Rong, H., Wang, D., Liu, X., Jin, K., Sun, Z., & Fan, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1009025 · Cited by 3
Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kühn, A., Park, J., Ghazi, A., & Aroda, V. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0832-3 · Cited by 4
Wysham, C., Lefèbvre, P., Pilon, D., Ingham, M., Lafeuille, M., Émond, B., Kamstra, R. L., Chow, W. S., Pfeifer, M. A., & Duh, M. S. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0180-8 · Cited by 4
“Improving renal and other outcomes (as opposed to targeting HbA1c) may also be of higher priority in older patients, particularly given the promising findings reported for SGLT2s and renal outcomes that have been recently reported [41, 42].”
BackgroundImpact of SGLT Inhibitors on Multiple Organ Defects in Diabetes
Asrih, M., & Gariani, K. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666191105151828 · Cited by 4
O’Hara, D. V., Neuen, B. L., & Jardine, M. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00809-x · Cited by 5
Self-citationInsulin and Other Hypoglycemic Drugs
(2018) · Side effects of drugs annual · doi:10.1016/bs.seda.2018.06.009 · Cited by 4
López‐Candales, A., Sawalha, K., Drees, B. M., & Norgard, N. B. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2181537 · Cited by 5
Zhou, Y., Wang, F., Wen, F.-F., Li, C., & Ye, T.-T. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2250949 · Cited by 4
Dorsey-Treviño, E. G., Contreras-Garza, B. M., González‐González, J. G., Álvarez‐Villalobos, N. A., Salcido‐Montenegro, A., González-Colmenero, A. D., Farrell, A. M., González‐Nava, V., Rodriguez‐Tamez, G., Montori, V. M., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020692 · Cited by 4
Slowing Progression of Chronic Kidney Disease
Pollack-Zollman, M., & Vassalotti, J. A. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190611620.003.0012 · Cited by 4
Agarwal, R., Hauske, S. J., Wheeler, D. C., Doi, K., Elsaesser, A., Ritter, I., Steubl, D., & Wanner, C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14694 · Cited by 4
Li, N., & Zhou, H. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220617153331 · Cited by 5
Diabetes Update 2017: Was ist neu in der Diabetologie? Welche Leitlinien müssen geändert werden?
Scherbaum, W. A. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0234-6 · Cited by 3
“Inzwischen wurde eine Arbeit publiziert, die zeigt, dass auch der SGLT-2Hemmer (SGLT-2: „sodium dependent glucose transporter 2“) Canagliflozin die Progression der Nierenfunktionsstörung bei Diabetes verlangsamt, und zwar unabhängig vom blutzuckerspiegelsenkenden Effekt diesesMedikaments ([26]; .”
BackgroundSukhareva, O. Y., Zuraeva, Z. T., & Shamhalova, M. (2022) · Diabetes Mellitus · doi:10.14341/dm12864 · Cited by 4
Zeng, L., Chen, L., Gao, F., Li, J., Song, Y., Wei, L., Qu, N., Li, Y., & Jiang, H. (2023) · Advanced Biology · doi:10.1002/adbi.202300199 · Cited by 3
Peppa, Μ., Manta, A., Mavroeidi, I., Asimakopoulou, A., Syrigos, A., Nastos, C., Pikoulis, E. A., & Κόλλιας, Α. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112526 · Cited by 5
Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects
Kim, K. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.2.74 · Cited by 3
Huang, C., Chen, C., Yy, H., & Hsu, B. (2020) · Journal of Postgraduate Medicine · doi:10.4103/jpgm.jpgm_680_19 · Cited by 3
“SGLT2 is have been associated with reductions in the progression of albuminuria in patients with type 2 diabetes.[21,22] Despite the initially acute decline in eGFR, trials with SGLT2is (canagliflozin and empagliflozin) have shown better preservation of eGFR during long-term administration than with comparators.”
ResultNorris, K. C., Williams, S. F., Nicholas, S. B., & Agodoa, L. Y. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804311-0.00019-4 · Cited by 8
Aoki, Y., Aoki, M., & Jenkins, D. J. A. (2017) · Cellular & Molecular Medicine Open access · doi:10.21767/2573-5365.100030 · Cited by 3
“Most recently, it has been demonstrated that SGTL 2 inhibitors slow progression of kidney disease in type 2 diabetes [8,9], where improvement of the bioavailability of vitamin C is not included in the putative mechanisms behind their renal effects.”
BackgroundIsidto, R., Danguilan, R. A., Naidas, O. D., Villanueva, R. T., Arakama, M.-H., & Paraiso, L. M. (2023) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s387262 · Cited by 5
Neumiller, J. J., Rhee, C. M., & Kalantar‐Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000484669 · Cited by 4
Li, C., Ng, J. K., Chan, G. C., Fung, W. W., Chow, K., & Szeto, C. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04677-0 · Cited by 2
“In additional to the traditional renin-angiotensin-aldosterone system (RAAS) blockers, sodium-glucose cotransporter 2 (SGLT2) inhibitors are efficacious in providing renal protection for both DKD and non-diabetic chronic kidney disease (CKD) [7–9].”
Rørth, R., Gerds, T. A., Kosjerina, V., Carstensen, B., Persson, F., & Rossing, P. R. (2025) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2025.100286 · Cited by 2
Kidney health for all: caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, Á., Yadla, M., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106360 · Cited by 2
“13,14 Serum creatinine remains the most widespread marker for routine assessment and monitoring of CKD but lacks sensitivity for early detection, 15 although this is essential to timely and effectively prevent progression.”
Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status
Correa‐Rotter, R., Rossing, P. R., Canziani, M. E., Caramori, M. L., Cherney, D. Z. I., Cronin, L., Hugo, C., Ji, B., Meyerhoff, J., Nangaku, M., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106545 · Cited by 2
“…an initial eGFR decline (also known as eGFR dip) of approximately 3 to 5 ml/min per 1.73 m 2 following initiation of treatment has been reported across SGLT2 inhibitor trials, 22-26 and a similar initial, reversible eGFR decline has been reported with renin-angiotensin-aldosterone inhibitors.”
InfluentialHabas, E., Rayani, A., Habas, A., Alarbi, K., Habas, A., Baghi, M., Habas, E., Errayes, E., Hamad, A., & Elzouki, A. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2688578 · Cited by 2
Kwon, H. (2016) · Journal of Korean Diabetes · doi:10.4093/jkd.2016.17.4.225 · Cited by 3
“또한 신장보호효과의 경우에 도 canagliflozin이 신기능악화를 지연시키고 미세알부민뇨 를 감소시킨다는 결과[17]를 가지고 있어서 공통적인 효과 로 생각해볼 여지가 있다.”
Yamaguchi, S., Shimabukuro, M., Tanaka, A., Imai, T., Hiramitsu, S., Takahashi, N., Kadokami, T., Ajioka, M., Suzuki, M., Node, K., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14876 · Cited by 2
SGLT2 Inhibitor: A Cardio-Renal Metabolic Pill
Krishnan, R., Subramanian, R., & Selvarajan, R. (2023) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20230119 · Cited by 2
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_1 · Cited by 2
Effects of Velagliflozin in 8 Cats With Diabetes Mellitus and Hypersomatotropism
Baldo, F. D., Corsini, A., Bresciani, F., Pergolese, V., Tirelli, I., Tardo, A. M., & Fracassi, F. (2025) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.70222 · Cited by 5
SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Rajput, R., & Ved, J. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.031 · Cited by 2
Recent important strategies in the management of chronic kidney disease
Meyers, A. M., & Davies, M. (2017) · South African Medical Journal · doi:10.7196/samj.2017.v107i9.12366 · Cited by 2
Geschlechtsunterschiede bei der diabetischen Nephropathie
Loeffler, I., & Wolf, G. (2020) · Der Nephrologe · doi:10.1007/s11560-020-00409-7 · Cited by 2
Sanyal, D., Majumder, A., Ghosh, S. K., & Pandit, K. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.01.011 · Cited by 3
Toth‐Manikowski, S. M., & Atta, M. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95806-9 · Cited by 2
Ma, Y., Lin, Y., Ding, X., & Peng, Y. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70176 · Cited by 1
Aoki, Y. (2016) · Diabetes Research - Open Journal · doi:10.17140/droj-2-128 · Cited by 1
Diabetestherapie bei chronischer Niereninsuffizienz
Bohnert, B. N., & Heni, M. (2018) · Dialyse aktuell · doi:10.1055/a-0582-3131 · Cited by 1
Sodium-Glucose Transporter Inhibitors and Diabetic Nephropathy in Humans and Animal Model
Nakhoul, R., Elias, K., Nakhoul, F. M., Dahan, I., Farber, E., Anam, H., & Nakhoul, N. (2018) · Journal of Clinical & Experimental Nephrology · doi:10.21767/2472-5056.100061 · Cited by 4
“The SGLT2 inhibitors, in addition to renal hemodynamic effects, including reducing glomerular hyperfiltration, also have inhibitory effects on the inflammatory and fibrotic responses of podocytes and proximal tubular cells to hyperglycaemia (Figure 1B) [35].”
Background
Metadata
- Authors
- Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V.
- Affiliations
- University Medical Center Groningen (NL)
- Janssen Research & Development (United States) (US)
- The University of Sydney (AU)
- Corresponding author
- Heerspink, Hiddo J. L.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-08-18
- Volume
- 28
- Issue
- 1
- Pages
- 368-375
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC5198289
- OpenAlex
- W2512006388
- Cited by
- 361
- References
- 22
- Citations by year
- 2026: 30 · 2025: 14 · 2024: 17 · 2023: 28 · 2022: 28 · 2021: 44 · 2020: 41 · 2019: 49 · 2018: 49 · 2017: 51 · 2016: 10
- FWCI
- 53.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, type 2 diabetes, renal function decline, EGFR, albuminuria, glimepiride, metformin, renal protection, glycemic control, albumin-creatinine ratio, dose-response relationship, diabetic nephropathy, secondary prevention, cardiovascular risk reduction, HbA1c
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Sulfonylurea Compounds, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.